When was Novozymes founded?

Novozymes was founded in 2000 and raised its 1st funding round within a year of its incorporation.

Where is Novozymes located?

Novozymes is headquartered in Bagsvaerd, Denmark. It is registered at 605 and 606, Everest Grande, 6th floor Mahakali Caves Road, Andheri East, Mumbai, Maharashtra, India, 400093.

How many employees does Novozymes have?

As of Mar 31, 2026, the latest employee count at Novozymes is 3104.

Is Novozymes a funded company?

Novozymes is a funded company, having raised a total of $9.75M across 15 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on 2000.

When was the latest funding round of Novozymes?

Novozymes' latest funding was a $***** Grant (prize money) round on Jun 01, 2021, with participation from 1 investor.

What is the annual revenue of Novozymes?

Annual revenue of Novozymes is more than $1B as on Dec 31, 2023

Where does Novozymes rank among its competitors?

Novozymes ranks 1st amongst 89 active competitors, of which 20 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Infinant Health, which secured $39.2M in May, 2026.

Who are the top competitors of Novozymes?

Novozymes' top competitors include Advanced Enzymes, Seres Therapeutics and Infinant Health. Among them, Infinant Health secured the most recent funding round in May, 2026.

Novozymes - 2026 Company Profile, Funding, Competitors & Financials

Novozymes is an acquired company based in Bagsvaerd (Denmark), founded in 2000. It operates as a Developer of biosolutions and enzymes for multiple industries and applications of biotechnology. Novozymes has raised $9.75M in funding. The company has 89 active competitors, including 20 funded and 13 that have exited. Its top competitors include companies like Advanced Enzymes, Seres Therapeutics and Infinant Health.

Company Details

Developer of biosolutions and enzymes for multiple industries and applications of biotechnology. It offers biosolutions using biotechnology, enzymes, microorganisms, and precision proteins to create sustainable products.The firm develops natural oral health treatments that affect the oral microbiota by using probiotics, enzymes, and bioactive to deliver solutions for human health. The firm provides Ronozyme feed enzymes that strengthen animal husbandry development.

Website: novozymes.com
Social
Registered Address: 605 and 606, Everest Grande, 6th floor Mahakali Caves Road, Andheri East, Mumbai, Maharashtra, India, 400093

Key Metrics

Founded Year

2000

Location

Bagsvaerd, Denmark

Stage

Acquired

Total Funding

$9.75M in 15 rounds

Latest Funding Round

Grant (prize money), Jun 01, 2021, $*****

Investors

DOE & 4 more

Ranked

1^st among 89 active competitors

Annual Revenue

$1B+ as on Dec 31, 2023

Employee Count

3,104 as on Mar 31, 2026

Investment & Acquisitions

Lyras & 16 more

Similar Companies

Seres Therapeutics & 90 more

Exit Details

Acquired by Kerry (Dec 12, 2023)

View Novozymes' full profile

Novozymes is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count
CHR.HANSEN (INDIA) PRIVATE LIMITED CIN: U15100MH2004PTC144042 , India, Active	Jan 16, 2004	₹100 - ₹500 Cr (As on Mar 31, 2025)	-
AKES INVESTMENTS LIMITED CIN: 10007127 , United Kingdom, Active	Feb 15, 2016	-	2 (As on Feb 28, 2022)
SYNERGIA LIFE SCIENCES PRIVATE LIMITED CIN: U15100MH2004PTC145390 , India, Active	Mar 29, 2004	₹100 - ₹500 Cr (As on Mar 31, 2025)	112 (As on Aug 31, 2025)
Novozymes Biopharma Dk A/s CIN: 29603537 , Denmark, Active	May 28, 2006	$1B+ (As on Dec 31, 2023)	-
UAS LIFE SCIENCES INDIA PRIVATE LIMITED CIN: U51397TG2014FTC093664 , India, Active	Mar 21, 2014	0 - ₹10 Cr (As on Mar 31, 2025)	-

Novozymes got acquired by Kerry on Dec 12, 2023.

Click here to take a look at Novozymes's acquisition in detail

Novozymes has raised a total funding of $9.75M over 15 rounds. Its first funding round was on 2000. Its latest funding round was a Grant (prize money) round on Jun 01, 2021 for $*****. 1 investor participated in its latest round. Novozymes has 5 institutional investors.

Here is the list of recent funding rounds of Novozymes:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jun 01, 2021	8832746	Grant (prize money)	9799628	5439318	9832233	3241707
Jun 01, 2020	9058017	Grant (prize money)	1480647	3549339	1573859	Europa
Jan 01, 2020	6537112	Grant (prize money)	5652844	1602712	6869333	Europa

Access funding benchmarks and valuations. Sign up today!

View details of Novozymes's funding rounds and investors

Novozymes' employee count trend

Novozymes has 3,104 employees as of Mar 26. Here is Novozymes's employee count trend over the years:

Uncover Novozymes' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Novozymes include Advanced Enzymes, Seres Therapeutics and Infinant Health. Here is the list of Top 10 competitors of Novozymes, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Novozymes 2000, Bagsvaerd (Denmark), Acquired	Developer of biosolutions and enzymes for multiple industries and applications of biotechnology	$9.75M	DOE, OSTI & 3 others	73/100
2nd	Advanced Enzymes 1989, Thane (India), Public	Manufacturer of enzymes for animal nutrition, baking, fruit and vegetable processing	-	Nalanda Capital, Avendus & 1 others	62/100
3rd	Seres Therapeutics 2010, Cambridge (United States), Public	Developer of microbiome therapeutics to treat a wide range of diseases	$134M	Flagship Pioneering, Mayo Clinic Business Accelerator ... & 8 others	60/100
4th	Infinant Health 2011, Norwalk (United States), Series C	Microbiome-based products to improve infant immune system	$39.2M	iSelect Fund, Gates & 4 others	59/100
5th	Biocodex 1953, Gentilly (France), Unfunded	Manufactures a range of health supplements and pharmaceuticals	-	-	59/100
6th	Genome & Company 2015, Seongnam-si (South Korea), Public	Developer of microbiome-based immuno-oncology drugs	-	IMM Investment, Timefolio Capital & 8 others	55/100
7th	Resbiotic 2021, Birmingham (United States), Series A	Provider of probiotic supplements to improve health	$20.6M	Timberline, Biostack Ventures & 3 others	55/100
8th	Nextbiotix 2016, Dijon (France), Series A	Developer of probiotic for the treatment of inflammatory bowel diseases	$30.4M	Crescent Enterprises, UI Investissement & 10 others	54/100
9th	Oragenics 1996, Tampa (United States), Public	Developer of novel treatments for infectious diseases and oral mucositis as well as probiotics for oral health	-	Third Security, Precigen & 3 others	53/100
10th	AMILI 2019, Singapore (Singapore), Series A	Provider of gut microbiome data insights, analytics, tests, and therapeutics	$10.5M	Vulcan Capital, East Ventures & 8 others	52/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Novozymes's competitors? Click here to see the top ones

Novozymes has made 5 investments in companies including Lyras and Plant Response. Novozymes has also acquired 12 companies including Synergia Life Sciences and Biota.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Mar 14, 2023	Investments	Lyras	2017	Aalborg (Denmark)
Nov 30, 2021	Acquisition	Synergia Life Sciences	2004	Iselin (United States)
Mar 11, 2021	Acquisition	Biota	2013	San Diego (United States)